IPCA Laboratories

IPCA Laboratories EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of IPCA Laboratories (IPCALAB.NS) as of Nov 3, 2026 is 23.34. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 31.29 — a change of -25.40% (lower).

EV/EBIT

23.34

YoY

-25.40%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of IPCA Laboratories is 2026 23.34 . EV/EBIT (Enterprise Value to EBIT) of IPCA Laboratories was 2025 31.29 . It decreases by -25.40% lower compared to the previous year.

The IPCA Laboratories EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
71.59 INR
Jan 1, 2020
53.25 INR
Jan 1, 2021
29.32 INR
Jan 1, 2022
35.95 INR
Jan 1, 2023
48.11 INR
Jan 1, 2024
38.79 INR
Jan 1, 2025
31.29 INR
Jan 1, 2026
23.34 INR
The IPCA Laboratories EV/EBIT history
YEAREV/EBITYoY
23.34-25.40%
31.29-19.34%
38.79-19.38%
48.11+33.83%
35.95+22.60%
29.32-44.94%
53.25-25.62%
71.59-42.99%
125.59-14.16%
146.30-35.33%
226.24+110.66%
107.39+107.07%
51.86+205.45%
16.98+14.88%
14.78+33.39%
11.08-28.84%
15.57+30.08%
11.97+73.48%
6.90-36.87%
10.93—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

IPCA Laboratories Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides IPCA Laboratories's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates IPCA Laboratories's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots IPCA Laboratories's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if IPCA Laboratories grows earnings faster than its peers.

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

EV/EBIT (Enterprise Value to EBIT) of IPCA Laboratories is 23.34 in 2026.

EV/EBIT (Enterprise Value to EBIT) of IPCA Laboratories changed from 31.29 to 23.34, representing a -25.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s IPCA Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — IPCA Laboratories

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — IPCA Laboratories